Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia

Cerebrospinal Fluid Proteomics For Identification Of α2-Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson’s Disease And Schizophrenia

Ashish Kumar Gupta,1,* Ruchika Pokhriyal,1,* Mohd Imran Khan,1 Domada Ratna Kumar,1 Rishab Gupta,2 Rakesh Kumar Chadda,2 Rashmi Ramachandran,3 Vinay Goyal,4 Manjari Tripathi,4 Gururao Hariprasad1 1Department of Biophysics; 2Department of Psychiatry; 3Department of Anaesthesia; 4Department of Neurolo...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Gupta AK, Pokhriyal R, Khan MI, Kumar DR, Gupta R, Chadda RK, Ramachandran R, Goyal V, Tripathi M, Hariprasad G
Format: article
Langue:EN
Publié: Dove Medical Press 2019
Sujets:
Parkinson's disease
Schizophrenia
iTRAQ proteomics
dopamine
biomarkers
therapeutic efficacy
alpha 2 macroglobulin
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Accès en ligne:https://doaj.org/article/aa0c375382c443d7b8415ff502d4a03b
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/aa0c375382c443d7b8415ff502d4a03b

Documents similaires